Decoy Therapeutics Inc. (DCOY): Submission of Matters to a Vote of Security Holders
Decoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001615219 false 0001615219 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14,
How this was made
The 30-second read
Why it matters
The disclosure confirms routine governance items: three Class II director elections, a non-binding advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Market read
Because the 8-K contains only final proxy vote tallies and no new financial or strategic information, it is unlikely to drive meaningful trading decisions.
What to watch
Traders should focus on any separate, contemporaneous catalysts (clinical, financing, partnerships) since this 8-K contains only meeting results.
Background
The company filed an SEC Form 8-K for Item 5.07, reporting matters submitted to a vote of security holders at its 2026 Annual Meeting.
Ticker impact
Decoy Therapeutics reported final voting results from its July 14, 2026 annual meeting, including director re-elections and auditor ratification.
Low likelihood of a sustained move; any reaction should be muted and short-lived.
The filing discloses standard outcomes: re-election of three Class II directors, non-binding advisory executive compensation approval, and ratification of Ernst & Young for 2026.
Market effects
No sector read-across; governance vote outcomes do not change biotech fundamentals in the text.
No regional market implications indicated.
No global relevance beyond the issuer’s corporate actions.
Counterpoint
If the market had been uncertain about board continuity or auditor selection, the confirmed vote could reduce overhang, but the filing provides no contentious outcome.
Key entities
- issuerDecoy Therapeutics Inc.
Nasdaq-listed company filing the 8-K with final annual meeting voting results.
- auditorErnst & Young LLP
Ratified as independent registered public accounting firm for fiscal year ending December 31, 2026.
